Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 10/20 | 0.61 |
| ▸ | CASR | P41180 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | VDR | P11473 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3633413 | 0.89 | GRM5 (0.78) | GRM5 | |
| SCHEMBL3634276 | 0.88 | GRM5 (0.79) | GRM5CASRCNR1CNR2NPSR1 | |
| SCHEMBL3635686 | 0.86 | GRM5 (0.58) | GRM5CASRALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL3633851 | 0.77 | GRM5 (0.79) | GRM5ALDH1A1SMN1; SMN2NPSR1KMT2A | |
| SCHEMBL3635570 | 0.76 | GRM5 (0.49) | GRM5CASRALDH1A1SMN1; SMN2VDR | |
| SCHEMBL3632587 | 0.76 | GRM5 (1.00) | GRM5ALDH1A1SMN1; SMN2 | |
| SCHEMBL3633520 | 0.76 | GRM5 (1.00) | GRM5 | |
| SCHEMBL3637919 | 0.76 | GRM5 (0.77) | GRM5CASRALDH1A1NPSR1 | |
| SCHEMBL3633417 | 0.76 | GRM5 (0.60) | GRM5SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3635996 | 0.76 | GRM5 (0.46) | GRM5CASRALDH1A1SMN1; SMN2VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2146969-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Novartis Ag (CH) | 2010-01-27 | — | — | EP | disclosed |
| US-20090105266-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-04-23 | — | — | US | disclosed |
| WO-2008128968-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | NOVARTIS AG (CH) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105266-A1 | Organic compounds | SLCO2B1, SLCO1B1, SLCO1B3 | GRM5 4545/4885CASR 3935/4885CNR1 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.